JP2011511806A5 - - Google Patents

Download PDF

Info

Publication number
JP2011511806A5
JP2011511806A5 JP2010546093A JP2010546093A JP2011511806A5 JP 2011511806 A5 JP2011511806 A5 JP 2011511806A5 JP 2010546093 A JP2010546093 A JP 2010546093A JP 2010546093 A JP2010546093 A JP 2010546093A JP 2011511806 A5 JP2011511806 A5 JP 2011511806A5
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
moiety
atoms
haloalkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2010546093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511806A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/033569 external-priority patent/WO2009100438A2/en
Publication of JP2011511806A publication Critical patent/JP2011511806A/ja
Publication of JP2011511806A5 publication Critical patent/JP2011511806A5/ja
Ceased legal-status Critical Current

Links

JP2010546093A 2008-02-07 2009-02-09 Ａｔｏｈ１発現を増強する化合物 Ceased JP2011511806A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2703208P 2008-02-07 2008-02-07
PCT/US2009/033569 WO2009100438A2 (en) 2008-02-07 2009-02-09 Compounds that enhance atoh-1 expression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014087579A Division JP5749829B2 (ja) 2008-02-07 2014-04-21 Ａｔｏｈ１発現を増強する化合物

Publications (2)

Publication Number Publication Date
JP2011511806A JP2011511806A (ja) 2011-04-14
JP2011511806A5 true JP2011511806A5 (enExample) 2012-03-29

Family

ID=40408118

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010546093A Ceased JP2011511806A (ja) 2008-02-07 2009-02-09 Ａｔｏｈ１発現を増強する化合物
JP2014087579A Expired - Fee Related JP5749829B2 (ja) 2008-02-07 2014-04-21 Ａｔｏｈ１発現を増強する化合物
JP2015099316A Expired - Fee Related JP6199340B2 (ja) 2008-02-07 2015-05-14 Ａｔｏｈ１発現を増強する化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2014087579A Expired - Fee Related JP5749829B2 (ja) 2008-02-07 2014-04-21 Ａｔｏｈ１発現を増強する化合物
JP2015099316A Expired - Fee Related JP6199340B2 (ja) 2008-02-07 2015-05-14 Ａｔｏｈ１発現を増強する化合物

Country Status (7)

Country Link
US (5) US8188131B2 (enExample)
EP (2) EP2254572B1 (enExample)
JP (3) JP2011511806A (enExample)
CN (1) CN101990433B (enExample)
AU (1) AU2009212135B2 (enExample)
CA (1) CA2714370C (enExample)
WO (1) WO2009100438A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
EP2786993B1 (en) 2007-08-13 2017-11-15 Monsanto Technology LLC Compositions and methods for controlling nematodes
AU2009212135B2 (en) 2008-02-07 2014-08-21 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
CN110194765A (zh) 2009-02-10 2019-09-03 孟山都技术有限公司 用于控制线虫的组合物和方法
WO2010098866A1 (en) * 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
ES2574253T3 (es) 2009-12-18 2016-06-16 Mitsubishi Tanabe Pharma Corporation Nuevo agente antiplaquetario
EP2560966B1 (en) * 2010-03-30 2021-01-06 Verseon International Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
EP2576783B1 (en) 2010-05-26 2017-11-29 CuRNA, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
EP2678050B1 (en) * 2011-02-24 2020-10-14 Emory University Noggin blocking compositions for ossification and methods related thereto
WO2013120107A1 (en) * 2012-02-09 2013-08-15 University Of Rochester Methods and compositions for treating a subject to inhibit hearing loss
JP6486272B2 (ja) * 2012-09-07 2019-03-20 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞および／または支持細胞再生のための方法および組成物
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
RU2641916C2 (ru) 2012-10-02 2018-01-23 Байер Кропсайенс Аг Гетероциклические соединения в качестве пестицидов
WO2014093622A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
US9079866B2 (en) 2013-02-04 2015-07-14 Janssen Pharmaceutica Nv Flap modulators
TWI644899B (zh) 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
ES2853483T3 (es) 2013-03-15 2021-09-16 Verseon Int Corporation Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa
WO2014145205A2 (en) * 2013-03-15 2014-09-18 St. Jude Children's Research Hospital Methods and compositions of p27kip1 transcription modulators
EP2970141B1 (en) 2013-03-15 2020-02-26 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
EP2991644B1 (en) 2013-04-04 2020-03-25 University of Maryland, Baltimore Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
EP3597755A1 (en) 2013-06-17 2020-01-22 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using viral components
SG11201510327TA (en) 2013-06-17 2016-01-28 Broad Inst Inc Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells
EP3653229A1 (en) 2013-12-12 2020-05-20 The Broad Institute, Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing
JP2017501149A (ja) 2013-12-12 2017-01-12 ザ・ブロード・インスティテュート・インコーポレイテッド 粒子送達構成成分を用いた障害及び疾患の標的化のためのｃｒｉｓｐｒ−ｃａｓ系及び組成物の送達、使用及び治療適用
US20150272999A1 (en) * 2014-03-31 2015-10-01 Banner Health Retrograde coronary vein delivery of stem cells
CN104072425B (zh) * 2014-07-09 2016-12-07 大连理工大学 苯并咪唑类化合物及其应用
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
BR112017004704A2 (pt) 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
EP3230452B1 (en) 2014-12-12 2025-06-11 The Broad Institute, Inc. Dead guides for crispr transcription factors
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
CA2970370A1 (en) 2014-12-24 2016-06-30 Massachusetts Institute Of Technology Crispr having or associated with destabilization domains
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
CN108137595B (zh) 2015-06-18 2021-04-20 听治疗有限责任公司 预防和治疗听力损失的方法和组合物
WO2016205749A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
JO3491B1 (ar) 2015-07-07 2020-07-05 Audion Therapeutics مركبات مثبطة لإشارات مسار notch
JP2017073472A (ja) * 2015-10-07 2017-04-13 株式会社ディスコ 半導体装置の製造方法
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) * 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
EP3562487B1 (en) 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
CN110461835A (zh) * 2017-03-24 2019-11-15 诺华股份有限公司 异噁唑甲酰胺化合物及其用途
MX388196B (es) 2017-04-26 2025-03-19 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
CN119410637A (zh) 2018-04-27 2025-02-11 分贝治疗公司 肌球蛋白15启动子及其用途
US11911416B2 (en) 2018-08-01 2024-02-27 University Of Iowa Research Foundation Compositions and methods to restore hearing loss and balance through embryonic ear transplant
US20220062281A1 (en) * 2018-08-13 2022-03-03 National Centre For Biological Sciences-Tifr Inhibitors to target hiv-1 nef-cd80/cd86 interactions for therapeutic intervention
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
EP3860562A1 (en) 2018-10-02 2021-08-11 Frequency Therapeutics, Inc. Pharmaceutical compositions comprising otic therapeutic agents and related methods
CN113544266A (zh) 2018-12-17 2021-10-22 博德研究所 Crispr相关转座酶系统和其使用方法
US12358893B2 (en) 2019-01-08 2025-07-15 Corxel Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
CN119320772A (zh) * 2019-02-08 2025-01-17 分贝治疗公司 肌球蛋白15启动子及其用途
EP3921032A4 (en) 2019-02-08 2022-11-30 Decibel Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF SENSORINEURAL HEARING LOSS USING OTOFERLIN DOUBLE VECTOR SYSTEMS
SG11202111191YA (en) 2019-04-08 2021-11-29 Frequency Therapeutics Inc Combination of chir99021 and valproic acid for treating hearing loss
WO2020236967A1 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Random crispr-cas deletion mutant
WO2021000928A1 (zh) * 2019-07-04 2021-01-07 中美瑞康核酸技术(南通)研究院有限公司 激活atoh1基因的寡聚核酸分子及其应用
US20220298501A1 (en) 2019-08-30 2022-09-22 The Broad Institute, Inc. Crispr-associated mu transposase systems
CA3153197A1 (en) 2019-10-03 2021-04-08 Ryan T. Gill Crispr systems with engineered dual guide nucleic acids
US20230340537A1 (en) 2020-01-17 2023-10-26 The Broad Institute, Inc. Small type ii-d cas proteins and methods of use thereof
EP4419672A2 (en) 2021-06-01 2024-08-28 Artisan Development Labs, Inc. Compositions and methods for targeting, editing, or modifying genes
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023149548A1 (ja) * 2022-02-03 2023-08-10 国立大学法人富山大学 新規医薬組成物
US20250388896A1 (en) 2022-03-01 2025-12-25 Celyntra Therapeutics Sa Composition and methods for transgene insertion
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3429890A (en) 1964-12-31 1969-02-25 Merck & Co Inc Certain 2-thiazolylbenzimidazole-1-oxy derivatives
US3686110A (en) 1970-02-27 1972-08-22 Meuch & Co Inc 1-oxybenzimidazoles
US3646049A (en) 1970-03-05 1972-02-29 Merck & Co Inc Acylaminobenzimidazole derivatives
US5342957A (en) 1988-11-29 1994-08-30 Janssen Pharmaceutica N.V. Benzimidazoles useful in treating epithelial disorders
US5157046A (en) 1988-11-29 1992-10-20 Janssen Pharmaceutica N.V. Method of treating epithelial disorders
US5140034A (en) * 1989-03-14 1992-08-18 Merck Sharp & Dohme Ltd. Five-membered ring systems with bonded imidazolyl ring substituents
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
WO1994014956A1 (en) 1992-12-23 1994-07-07 Iowa State University Research Foundation, Inc. Molecular flashlight
WO1996019991A1 (en) 1994-12-28 1996-07-04 Janssen Pharmaceutica N.V. Benzimidazoles as inhibitors of calcitriol metabolism
CA2248013A1 (en) 1996-03-11 1997-09-18 Eli Lilly And Company Methods of treating or preventing interstitial cystitis
GB2326760B (en) 1997-06-28 2002-02-13 Mitel Semiconductor Ab Optical source with monitor
US6339782B1 (en) 1997-11-21 2002-01-15 International Business Machines Corporation Persistence mechanism and method for objects
JP2003530817A (ja) 1999-06-01 2003-10-21 ベイラー カレッジ オブ メディスン 聴覚障害、変形性関節症および細胞の異常増殖に関するａｔｏｎａｌ関連配列の治療用途のための組成物および方法
US20020192665A1 (en) * 1999-06-01 2002-12-19 Zoghbi Huda Y. Compositions and methods for the therapeutic use of an atonal-associated sequence for a gastrointestinal condition
SK2512002A3 (en) * 1999-08-19 2002-07-02 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
AU2002221239A1 (en) * 2000-12-07 2002-06-18 Astrazeneca Ab Therapeutic benzimidazole compounds
US7405235B2 (en) 2001-05-04 2008-07-29 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CA2445515A1 (en) * 2001-05-04 2002-11-04 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
KR20040004705A (ko) * 2001-06-08 2004-01-13 시토비아 인크. 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
US6855714B2 (en) 2001-07-06 2005-02-15 Schering Aktiengesellschaft 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives
US20030082362A1 (en) 2001-07-31 2003-05-01 Khandpur Ashish K. High cohesive strength pressure sensitive adhesive foam
ATE529110T1 (de) 2002-03-05 2011-11-15 Transtech Pharma Inc Mono- und bicyclische azolderivate die die interaktion von liganden mit rage hemmen
US7206639B2 (en) 2002-03-15 2007-04-17 Sarcos Investments Lc Cochlear drug delivery system and method
US7867193B2 (en) 2004-01-29 2011-01-11 The Charles Stark Draper Laboratory, Inc. Drug delivery apparatus
US20040106553A1 (en) 2002-06-24 2004-06-03 Alekshun Michael N. Methods for preventing and treating microbial infections by modulating transcription factors
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
EP3345895B1 (en) * 2003-04-11 2019-12-04 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
NZ545864A (en) 2003-09-22 2009-12-24 S Bio Pte Ltd Benzimidazole derivates: preparation and pharmaceutical applications
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
AU2005324492B2 (en) * 2004-04-23 2012-06-07 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
CN1993363A (zh) * 2004-08-03 2007-07-04 默克公司 1,3－二取代的杂芳基nmda/nr2b拮抗剂
JP2006117536A (ja) 2004-10-19 2006-05-11 Kyoto Univ 内耳の有毛細胞を誘導するための医薬
WO2006050053A2 (en) 2004-11-01 2006-05-11 Nuada, Llc Compounds and methods of use thereof
CA2618370A1 (en) * 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Oxazolopyridine derivatives as sirtuin modulators
WO2007030743A2 (en) 2005-09-08 2007-03-15 Massachusetts Eye & Ear Infirmary Cochlear implants containing biological cells and uses thereof
KR20080087833A (ko) 2005-12-21 2008-10-01 쉐링 코포레이션 히스타민 ｈ３ 길항제로서 유용한 페녹시피페리딘 및 이의유사체
EP1966143A2 (en) 2005-12-21 2008-09-10 Schering Corporation Substituted aniline derivatives useful as histamine h3 antagonists
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2009005551A2 (en) 2007-03-27 2009-01-08 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
US7947723B2 (en) 2008-02-01 2011-05-24 Spelman College Synthesis and anti-proliferative effect of benzimidazole derivatives
AU2009212135B2 (en) 2008-02-07 2014-08-21 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression

Similar Documents

Publication Publication Date Title
JP2011511806A5 (enExample)
US12565515B2 (en) 1,2,4-oxadiazole compounds as inhibitors of CD47 signalling pathways
US10905701B2 (en) Compositions and methods for inhibiting arginase activity
JP2006501201A5 (enExample)
EA201000808A1 (ru) Индольные соединения и способы лечения висцеральной боли
JP2010530881A5 (enExample)
RU2012138257A (ru) Замещенные пирролидин-2-карбоксамиды
US20140179750A1 (en) Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
RU2010126056A (ru) Органические соединения
RU2008125065A (ru) ОНКОГЕННОЕ Ras-СПЕЦИФИЧЕСКОЕ ЦИТОТОКСИЧЕСКОЕ СОЕДИНЕНИЕ И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
JP2009536191A5 (enExample)
RU2354655C2 (ru) Ингибиторы сомт
EA201000486A1 (ru) Ингибитор белка, активирующего 5-липоксигеназу (flap)
JP2013533253A5 (enExample)
US20250144060A1 (en) Compositions and methods for treating biofilms
JP2018507257A5 (enExample)
EP2722328A1 (fr) Nouveaux composés ayant une activité protectrice vis-à-vis de toxines au mode d'action intracellulaire
PE20081703A1 (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
SK8495A3 (en) Chiral 1-imidazoletanol derivatives, method of their production and intermediates on their production
US11771688B2 (en) Pyridine derivatives substituted by heterocyclic ring and amino group
JP2011508779A5 (enExample)
ES2700527T3 (es) Compuesto de fenoxialquilamina
US11077097B2 (en) Use of aromatic ring drug in inhibiting key transcription factor of malignant melanoma
ES2607752T3 (es) Compuestos nuevos para regeneración de células y tejidos terminalmente diferenciados
TW200427458A (en) Crystalline N-formyl hydroxylamine compounds